Anixa Biosciences (NASDAQ:ANIX) Upgraded at Zacks Research

Zacks Research upgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a hold rating to a strong-buy rating in a research note released on Monday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Thursday, September 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Tuesday, October 14th. Finally, D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Anixa Biosciences Price Performance

Shares of NASDAQ:ANIX opened at $4.04 on Monday. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.98. The company has a 50 day moving average of $3.44 and a 200-day moving average of $3.14. The stock has a market cap of $133.00 million, a price-to-earnings ratio of -11.54 and a beta of 0.69.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Wednesday, September 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. Equities research analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, July 31st. The stock was acquired at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the director owned 953,334 shares of the company’s stock, valued at $2,936,268.72. This trade represents a 1.06% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 25.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ANIX. NewEdge Advisors LLC acquired a new position in Anixa Biosciences during the second quarter worth $33,000. Private Advisor Group LLC bought a new stake in Anixa Biosciences during the first quarter worth $35,000. Benjamin Edwards Inc. bought a new stake in Anixa Biosciences during the second quarter worth $37,000. Marshall Wace LLP bought a new stake in Anixa Biosciences during the second quarter worth $39,000. Finally, World Investment Advisors bought a new stake in Anixa Biosciences during the third quarter worth $48,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.